Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

This is the third indication under clinical development for soquelitinib, which is also in a registrational Phase 3 trial for peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Do you know about this pathbreaking cancer therapy?.

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Enrollment in MAD portion of the trial continues with higher doses being evaluated OXFORDSHIRE, UK & CONSHOHOCKEN, PA & GAITHERSBURG, MD, USA I March 10, 2025 I Immunocore Holdings plc (Nasdaq: IMCR) ...

The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...

Sex differences in the risk factors, diagnosis, treatment, and outcomes of patients with cardiovascular disease have been ...

One of the hardest lessons learned occurred after I inadvertently failed at communication and education before transferring a ...